Southwest oncology group phase II study of ispinesib in androgen-independent prostate cancer previously treated with taxanes

Clinical Genitourinary Cancer

Volumn 6, Issue 2, 2008, Pages 103-109

  Beer, Tomasz M ^a,k   Goldman, Bryan ^b   Synold, Timothy W ^c   Ryan, Christopher W ^a   Vasist, Lakshmi S ^d   Van Veldhuizen, Peter J ^e   Dakhil, Shaker R ^f   Lara, Primo N ^g   Drelichman, Anibal ^h   Hussain, Maha H A ⁱ   Crawford, E David ^j  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b Statistical Center   (United States)

^c CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^d GLAXOSMITHKLINE   (United States)

^e UNIVERSITY OF KANSAS MEDICAL CENTER   (United States)

^f Wichita Community Clinical   (United States)

^g UNIVERSITY OF CALIFORNIA   (United States)

^h PROVIDENCE HOSPITAL   (United States)

ⁱ UNIVERSITY OF MICHIGAN   (United States)

^j UNIVERSITY OF COLORADO   (United States)

^k OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

more..

Author keywords

Hela cells; Kinesin spindle protein; Mitosis; Peripheral blood; Prostate specific antigen

Indexed keywords

ANDROGEN; DOCETAXEL; ISPINESIB; KINESIN; PROSTATE SPECIFIC ANTIGEN; BENZAMIDE DERIVATIVE; KIF11 PROTEIN, HUMAN; QUINAZOLINE DERIVATIVE; TAXOID; UNCLASSIFIED DRUG;

ADULT; AGED; ALKALINE PHOSPHATASE BLOOD LEVEL; ANEMIA; ANOREXIA; ARTHRALGIA; ARTICLE; BLOOD; BLOOD TOXICITY; BONE PAIN; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CLINICAL TRIAL; COMPARATIVE STUDY; CONSTIPATION; CONTROLLED STUDY; CYSTITIS; DIZZINESS; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG EFFICACY; DRUG WITHDRAWAL; DYSPNEA; FATIGUE; FEBRILE NEUTROPENIA; FEVER; HOT FLUSH; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPERGLYCEMIA; HYPOALBUMINEMIA; HYPONATREMIA; IMMUNOHISTOCHEMISTRY; LEUKOPENIA; LYMPHOCYTE; LYMPHOCYTOPENIA; MALE; MOUTH PAIN; MULTIPLE CYCLE TREATMENT; MUSCLE WEAKNESS; NEUROTOXICITY; NEUTROPENIA; ONCOLOGY; PHARMACODYNAMICS; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; POPULATION; PROGRESSION FREE SURVIVAL; PROSTATE ADENOCARCINOMA; PROTEIN EXPRESSION; SIDE EFFECT; THROMBOCYTOPENIA; URINARY TRACT INFECTION; URINE RETENTION; DISEASE FREE SURVIVAL; DRUG ANTAGONISM; DRUG RESISTANCE; DRUG SCREENING; MIDDLE AGED; PROSTATE TUMOR;

AGED; AGED, 80 AND OVER; BENZAMIDES; DISEASE-FREE SURVIVAL; DRUG EVALUATION; DRUG RESISTANCE, NEOPLASM; HUMANS; KINESIN; MALE; MIDDLE AGED; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; QUINAZOLINES; TAXOIDS;

EID: 58149190803     PISSN: 15587673     EISSN: None     Source Type: Journal    
DOI: 10.3816/CGC.2008.n.016     Document Type: Article

References (10)

1. (Pubitemid 39315317) Tannock IF, de Wit R, Berry WR, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004; 351: 1502-12.
2. Petrylak Dp, Tangen CM, Hussain MH, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004; 351: 1513-20.
3. (Pubitemid 29517916) Wood KW, Cornwell WD, Jackson JR. Past and future of the mitotic spindle as an oncology target. Curr Opin Pharmacol 2001; 1: 370-7.
4. Lee Y, Zhiheng J, Sakowicz R. Inhibitors of the mitotic kinesin KSP: biochemical mechanism of action. Proc Am Assoc Cancer Res 2002; 43: 65.
5. Johnson RK, McCabe FL, Caulder E, et al. SB-715992, a potent and selective inhibitor of the mitotic kinesin KSP, demonstrates broad-spectrum activity in advanced murine tumors and human tumor xenografts. Proc Am Assoc Cancer Res 2002; 43: 269.
6. Gonzales P, Boehme M, Bienek A, et al. Breadth of anti-tumor activity of CK0238273 (SB-715992), a novel inhibitor of the mitotic kinesin KSP. Proc Am Assoc Cancer Res 2002; 43: 269.
7. Chu QS, Holen KD, Rowinsky EK, et al. Phase I trial of novel kinesin spindle protein (KSP) inhibitor SB-715992 IV q 21 days. Proc Am Soc Clin Oncol 2004; 23 (14 suppl) : 146 (Abstract 2078).
8. Bubley GJ, Carducci M, Dahut W, et al. Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group. J Clin Oncol 1999; 17: 3461-7.
9. Outcomes of cancer treatment for technology assessment and cancer treatment guidelines. American Society of Clinical Oncology. J Clin Oncol 1996; 14: 671-9.
10. Davis DA, Sarkar SH, Hussain M, et al. Increased therapeutic potential of an experimental anti-mitotic inhibitor SB715992 by genistein in PC-3 human prostate cancer cell line. BMC Cancer 2006; 6: 22.